Document 1105
 DOCN  M94A1105
 TI    Antiviral response to nevirapine monotherapy in nucleoside naive
       persons. Dutch-Italian-Australian Nevirapine Study Group.
 DT    9412
 AU    de Jong M; NATEC, Amsterdam, The Netherlands.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):208 (abstract no. PB0847). Unique
       Identifier : AIDSLINE ICA10/94371470
 AB    OBJECTIVE: Assess safety and antiretroviral activity of nevirapine (nvp)
       at a dosage of 400 mg/day in p24 antigenemic nucleoside naive patients.
       METHODS: Twenty p24 antigen positive males who had not received prior
       antiretroviral treatment were treated with nvp 200 mg/day for two weeks,
       followed by nvp 400 mg/day. Median values of baseline CD4+ cell counts
       and p24 antigen levels were 248 cells/mm3 (range 74-419), and 61 pg/ml
       (range 22-507) respectively. Antiretroviral activity was evaluated in
       terms of p24 antigen levels and CD4+ cell counts. Additional RNA load
       and resistance studies were planned. RESULTS: Rash and liver enzyme
       abnormalities were observed resulting in premature discontinuation in 4
       patients. During the first four weeks of treatment, 18/20 patients
       reached 50% declines in p24 antigen levels. However, the duration of p24
       antigen declines was variable: after 16, 20 and 24 weeks of treatment,
       p24 antigen levels were still 50% below baseline values in respectively
       9/14, 5/11, and 2/7 patients. A transient increase in median CD4+ count
       was followed by a return to baseline values within 12 weeks. Follow-up
       data up to 24 weeks will be presented. CONCLUSION: Nevirapine 400 mg
       results in p24 antigen declines of variable duration. Further research
       will be presented, evaluating whether virologic, host, or
       pharmacokinetic factors can predict duration of response.
 DE    Antiviral Agents/*THERAPEUTIC USE  Human  HIV Core Protein p24/*ANALYSIS
       HIV Infections/*DRUG THERAPY/IMMUNOLOGY/MICROBIOLOGY  Leukocyte Count
       Male  Pyridines/*THERAPEUTIC USE  T4 Lymphocytes  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).